The pharmaceutical company Farmak (Kyiv) stands for mutual recognition of the results of good manufacturing practice (GMP) checks in production of medicines within the framework of the Ukraine-EU industrial dialogue. “A key prerequisite for realizing cooperation opportunities between the Ukrainian and European pharmaceutical sectors is to update the scope of the future ACAA agreement (Agreement on Conformity Assessment and Acceptance of Industrial Goods) with the EU. First of all, to include provisions on the mutual recognition of the results of audits of good manufacturing practice in the pharmaceutical sector (GMP),” Yevhenia Piddubna, the director for corporate communications at Farmak, told Interfax-Ukraine.
She also noted the high potential for the participation of the Ukrainian pharmaceutical industry in the diversification of European supply chains for critical medicines in the face of the COVID-19 pandemic.
Farmak is one of the oldest pharmaceutical companies in Ukraine, specializing in the production of modern high-tech drugs. At the company’s production sites, a pharmaceutical quality system has been introduced and it is constantly being improved in accordance with the current regulatory requirements and in accordance with international standards: ISO, GMP (Good Manufacturing Practice). The company undergoes several international inspections and audits annually.
The company is included in the top 100 largest taxpayers in Ukraine. In 2020, Farmak paid taxes totaling more than UAH 712 million, including UAH 120 million to the Kyiv city budget.
Farmak is a member of the Manufacturers of Medications of Ukraine association.
